Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
|Articles|July 12, 2021
ASPC 2021 Virtual Summit on CVD Prevention Taking Place July 23-25
Author(s)HCP Live
The virtual sessions will cover a litany of topics in the greater spectrum of cardiovascular disease prevention and care.
Advertisement
The American Society for Preventive Cardiology (ASPC) has announced their 2021 Virtual Summit on CVD Prevention will take place from July 23-25, 2021.
The ASPC emphasized the event will focus on the inclusiveness and the care of one and all at risk for cardiovascular disease.
The event is for a wide variety of physicians, researchers, and other healthcare professionals to engage with cutting-edge lectures, lively debates, and practical applications.
Presenters will explore the broad spectrum of preventive cardiology led by world-renowned experts in the field of cardiology.
Topics covered will include:
- Emerging Therapies for Lipid Management
- CAC vs. Biomarkers
- Chest Pain Guidelines and Imaging
- Prevention of Heart Failure
- Atrial Fibrillation
- PAD Evaluation, Treatment, and Management
- Practical Application of New Prevention Therapies
- CVD Prevention in Special Populations
Advertisement
Related to this article
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Edaravone dexborneol before thrombectomy improved 90-day independence only in LVO stroke patients with clinical-radiological mismatch in TASTE-2.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
5